ロード中...
Targeting Solid Tumors With BTK Inhibitors
The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients. Here we review the emerging evidence regarding the clinical potential of BTK inhibitors in solid tumor therapy. The use...
保存先:
| 出版年: | Front Cell Dev Biol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8079762/ https://ncbi.nlm.nih.gov/pubmed/33937249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2021.650414 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|